Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Increased myocardial .

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Bauckneht M, Pastorino F, Castellani P, Cossu V, Orengo AM, Piccioli P, Emionite L, Capitanio S, Yosifov N, Bruno S, Lazzarini E, Ponzoni M, Ameri P, Rubartelli A, Ravera S, Morbelli S, Sambuceti G, Marini C.
PMID: 30737636
J Nucl Cardiol. 2020 Dec;27(6):2183-2194. doi: 10.1007/s12350-019-01618-x. Epub 2019 Feb 08.

BACKGROUND: Oxidative stress and its interference on myocardial metabolism play a major role in Doxorubicin (DXR) cardiotoxic cascade.METHODS: Mice models of neuroblastoma (NB) were treated with 5 mg DXR/kg, either free (Free-DXR) or encapsulated in untargeted (SL[DXR]) or in...

Cite
Bauckneht M, Pastorino F, Castellani P, et al. Increased myocardial . J Nucl Cardiol. 2019;27(6):2183-2194doi: 10.1007/s12350-019-01618-x.
Bauckneht, M., Pastorino, F., Castellani, P., Cossu, V., Orengo, A. M., Piccioli, P., Emionite, L., Capitanio, S., Yosifov, N., Bruno, S., Lazzarini, E., Ponzoni, M., Ameri, P., Rubartelli, A., Ravera, S., Morbelli, S., Sambuceti, G., & Marini, C. (2020). Increased myocardial . Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 27(6), 2183-2194. https://doi.org/10.1007/s12350-019-01618-x
Bauckneht, Matteo, et al. "Increased myocardial ." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 27,6 (2020): 2183-2194. doi: https://doi.org/10.1007/s12350-019-01618-x
Bauckneht M, Pastorino F, Castellani P, Cossu V, Orengo AM, Piccioli P, Emionite L, Capitanio S, Yosifov N, Bruno S, Lazzarini E, Ponzoni M, Ameri P, Rubartelli A, Ravera S, Morbelli S, Sambuceti G, Marini C. Increased myocardial . J Nucl Cardiol. 2020 Dec;27(6):2183-2194. doi: 10.1007/s12350-019-01618-x. Epub 2019 Feb 08. PMID: 30737636.
Copy Download .nbib Format: NLM
Abscisic Acid's Role in the Modulation of Compounds that Contribute to Wine Quality.

Plants (Basel, Switzerland)

Alonso R, Berli FJ, Fontana A, Piccoli P, Bottini R.
PMID: 34066656
Plants (Basel). 2021 May 08;10(5). doi: 10.3390/plants10050938.

Abscisic acid (ABA) plays a crucial role in the plant responses to environmental signals, in particular by triggering secondary metabolism. High-altitude vineyards in Mendoza, Argentina, are exposed to elevated solar ultraviolet-B (UV-B) levels and moderate water deficits (WD), thus...

Cite
Alonso R, Berli FJ, Fontana A, et al. Abscisic Acid's Role in the Modulation of Compounds that Contribute to Wine Quality. Plants (Basel). 2021;10(5)doi: 10.3390/plants10050938.
Alonso, R., Berli, F. J., Fontana, A., Piccoli, P., & Bottini, R. (2021). Abscisic Acid's Role in the Modulation of Compounds that Contribute to Wine Quality. Plants (Basel, Switzerland), 10(5), . https://doi.org/10.3390/plants10050938
Alonso, Rodrigo, et al. "Abscisic Acid's Role in the Modulation of Compounds that Contribute to Wine Quality." Plants (Basel, Switzerland) vol. 10,5 (2021). doi: https://doi.org/10.3390/plants10050938
Alonso R, Berli FJ, Fontana A, Piccoli P, Bottini R. Abscisic Acid's Role in the Modulation of Compounds that Contribute to Wine Quality. Plants (Basel). 2021 May 08;10(5). doi: 10.3390/plants10050938. PMID: 34066656; PMCID: PMC8151882.
Copy Download .nbib Format: NLM
Effect of a topical gel based on Adelmidrol + Trans-traumatic acid in the treatment of diabetic foot ulcers: an open-label study.

Journal of the American Podiatric Medical Association

Teobaldi I, Stoico V, Perrone F, Mantovani A, Piccagli P, Grandi F, Baldo B.
PMID: 34709395
J Am Podiatr Med Assoc. 2021 Oct 28; doi: 10.7547/20-143. Epub 2021 Oct 28.

BACKGROUND: Diabetic foot ulceration is a severe complication of diabetes characterized by chronic inflammation and impaired wound healing. This study aims to evaluate the effect of a medical device gel based on Adelmidrol + Trans traumatic acid in the...

Cite
Teobaldi I, Stoico V, Perrone F, et al. Effect of a topical gel based on Adelmidrol + Trans-traumatic acid in the treatment of diabetic foot ulcers: an open-label study. J Am Podiatr Med Assoc. 2021;doi: 10.7547/20-143.
Teobaldi, I., Stoico, V., Perrone, F., Mantovani, A., Piccagli, P., Grandi, F., & Baldo, B. (2021). Effect of a topical gel based on Adelmidrol + Trans-traumatic acid in the treatment of diabetic foot ulcers: an open-label study. Journal of the American Podiatric Medical Association, . https://doi.org/10.7547/20-143
Teobaldi, Ilaria, et al. "Effect of a topical gel based on Adelmidrol + Trans-traumatic acid in the treatment of diabetic foot ulcers: an open-label study." Journal of the American Podiatric Medical Association vol. (2021). doi: https://doi.org/10.7547/20-143
Teobaldi I, Stoico V, Perrone F, Mantovani A, Piccagli P, Grandi F, Baldo B. Effect of a topical gel based on Adelmidrol + Trans-traumatic acid in the treatment of diabetic foot ulcers: an open-label study. J Am Podiatr Med Assoc. 2021 Oct 28; doi: 10.7547/20-143. Epub 2021 Oct 28. PMID: 34709395.
Copy Download .nbib Format: NLM
Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.

Cancer medicine

Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P.
PMID: 34796694
Cancer Med. 2022 Jan;11(1):183-193. doi: 10.1002/cam4.4371. Epub 2021 Nov 18.

Triple negative breast cancers (TNBCs) are very aggressive and have a poor prognosis due to lack of efficacious therapies. The only effective treatment is chemotherapy that however is frequently hindered by the occurrence of drug resistance. We approached this...

Cite
Balza E, Carlone S, Carta S, et al. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med. 2021;11(1):183-193doi: 10.1002/cam4.4371.
Balza, E., Carlone, S., Carta, S., Piccioli, P., Cossu, V., Marini, C., Sambuceti, G., Rubartelli, A., & Castellani, P. (2022). Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer medicine, 11(1), 183-193. https://doi.org/10.1002/cam4.4371
Balza, Enrica, et al. "Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models." Cancer medicine vol. 11,1 (2022): 183-193. doi: https://doi.org/10.1002/cam4.4371
Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med. 2022 Jan;11(1):183-193. doi: 10.1002/cam4.4371. Epub 2021 Nov 18. PMID: 34796694.
Copy Download .nbib Format: NLM
Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.

Cancer medicine

Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P.
PMID: 34796694
Cancer Med. 2022 Jan;11(1):183-193. doi: 10.1002/cam4.4371. Epub 2021 Nov 18.

Triple negative breast cancers (TNBCs) are very aggressive and have a poor prognosis due to lack of efficacious therapies. The only effective treatment is chemotherapy that however is frequently hindered by the occurrence of drug resistance. We approached this...

Cite
Balza E, Carlone S, Carta S, et al. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med. 2021;11(1):183-193doi: 10.1002/cam4.4371.
Balza, E., Carlone, S., Carta, S., Piccioli, P., Cossu, V., Marini, C., Sambuceti, G., Rubartelli, A., & Castellani, P. (2022). Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer medicine, 11(1), 183-193. https://doi.org/10.1002/cam4.4371
Balza, Enrica, et al. "Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models." Cancer medicine vol. 11,1 (2022): 183-193. doi: https://doi.org/10.1002/cam4.4371
Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med. 2022 Jan;11(1):183-193. doi: 10.1002/cam4.4371. Epub 2021 Nov 18. PMID: 34796694; PMCID: PMC8704177.
Copy Download .nbib Format: NLM
The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation.

Pediatric reports

Mauro M, Camoglio F, Piccoli P, De Bortoli M, Balter R, Pegoraro A, Cesaro S.
PMID: 27114815
Pediatr Rep. 2016 Mar 31;8(1):6159. doi: 10.4081/pr.2016.6159. eCollection 2016 Mar 31.

In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and splenectomy. We describe here three...

Cite
Mauro M, Camoglio F, Piccoli P, et al. The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation. Pediatr Rep. 2016;8(1):6159doi: 10.4081/pr.2016.6159.
Mauro, M., Camoglio, F., Piccoli, P., De Bortoli, M., Balter, R., Pegoraro, A., & Cesaro, S. (2016). The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation. Pediatric reports, 8(1), 6159. https://doi.org/10.4081/pr.2016.6159
Mauro, Margherita, et al. "The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation." Pediatric reports vol. 8,1 (2016): 6159. doi: https://doi.org/10.4081/pr.2016.6159
Mauro M, Camoglio F, Piccoli P, De Bortoli M, Balter R, Pegoraro A, Cesaro S. The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation. Pediatr Rep. 2016 Mar 31;8(1):6159. doi: 10.4081/pr.2016.6159. eCollection 2016 Mar 31. PMID: 27114815; PMCID: PMC4821215.
Copy Download .nbib Format: NLM
Nanomaterial Gas Sensors for Online Monitoring System of Fruit Jams.

Foods (Basel, Switzerland)

Núñez-Carmona E, Abbatangelo M, Zottele I, Piccoli P, Tamanini A, Comini E, Sberveglieri G, Sberveglieri V.
PMID: 31810272
Foods. 2019 Dec 02;8(12). doi: 10.3390/foods8120632.

Jams are appreciated worldwide and have become a growing market, due to the greater attention paid by consumers for healthy food. The selected products for this study represent a segment of the European market that addresses natural products without...

Cite
Núñez-Carmona E, Abbatangelo M, Zottele I, et al. Nanomaterial Gas Sensors for Online Monitoring System of Fruit Jams. Foods. 2019;8(12)doi: 10.3390/foods8120632.
Núñez-Carmona, E., Abbatangelo, M., Zottele, I., Piccoli, P., Tamanini, A., Comini, E., Sberveglieri, G., & Sberveglieri, V. (2019). Nanomaterial Gas Sensors for Online Monitoring System of Fruit Jams. Foods (Basel, Switzerland), 8(12), . https://doi.org/10.3390/foods8120632
Núñez-Carmona, Estefanía, et al. "Nanomaterial Gas Sensors for Online Monitoring System of Fruit Jams." Foods (Basel, Switzerland) vol. 8,12 (2019). doi: https://doi.org/10.3390/foods8120632
Núñez-Carmona E, Abbatangelo M, Zottele I, Piccoli P, Tamanini A, Comini E, Sberveglieri G, Sberveglieri V. Nanomaterial Gas Sensors for Online Monitoring System of Fruit Jams. Foods. 2019 Dec 02;8(12). doi: 10.3390/foods8120632. PMID: 31810272; PMCID: PMC6963516.
Copy Download .nbib Format: NLM
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.

Journal of translational medicine

Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D'Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP.
PMID: 26801979
J Transl Med. 2016 Jan 22;14:24. doi: 10.1186/s12967-016-0779-y.

No abstract available.

Cite
Boero S, Morabito A, Banelli B, et al. Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2016;14:24doi: 10.1186/s12967-016-0779-y.
Boero, S., Morabito, A., Banelli, B., Cardinali, B., Dozin, B., Lunardi, G., Piccioli, P., Lastraioli, S., Carosio, R., Salvi, S., Levaggi, A., Poggio, F., D'Alonzo, A., Romani, M., Del Mastro, L., Poggi, A., & Pistillo, M. P. (2016). Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. Journal of translational medicine, 1424. https://doi.org/10.1186/s12967-016-0779-y
Boero, Silvia, et al. "Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines." Journal of translational medicine vol. 14 (2016): 24. doi: https://doi.org/10.1186/s12967-016-0779-y
Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D'Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2016 Jan 22;14:24. doi: 10.1186/s12967-016-0779-y. PMID: 26801979; PMCID: PMC4724068.
Copy Download .nbib Format: NLM
Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization.

Heart international

Muneretto C, Bisleri G, Negri A, Piccoli P, Nodari S, Dei Cas L.
PMID: 21977263
Heart Int. 2006;2(3):136. doi: 10.4081/hi.2006.136. Epub 2006 Dec 15.

OBJECTIVES: Diabetes negatively affects the outcome of patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or coronary surgery. However, data are lacking with respect to the impact of arterial revascularization in the diabetic population.METHODS: Between 1999 and 2003, 100 of...

Cite
Muneretto C, Bisleri G, Negri A, et al. Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. Heart Int. 2006;2(3):136doi: 10.4081/hi.2006.136.
Muneretto, C., Bisleri, G., Negri, A., Piccoli, P., Nodari, S., & Dei Cas, L. (2006). Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. Heart international, 2(3), 136. https://doi.org/10.4081/hi.2006.136
Muneretto, Claudio, et al. "Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization." Heart international vol. 2,3 (2006): 136. doi: https://doi.org/10.4081/hi.2006.136
Muneretto C, Bisleri G, Negri A, Piccoli P, Nodari S, Dei Cas L. Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. Heart Int. 2006;2(3):136. doi: 10.4081/hi.2006.136. Epub 2006 Dec 15. PMID: 21977263; PMCID: PMC3184675.
Copy Download .nbib Format: NLM
Measurement of the negative muon spectrum between 0.3 and 40 GeV/c in the atmosphere.

Physical review. D, Particles and fields

Basini G, Bellotti R, Bongiorno F, Brunetti MT, Cafagna F, Circella M, Codino A, De Cataldo G, De Marzo CN, De Pascale MP, Giglietto N, Golden RL, Grimani C, Massimo Brancaccio F, Menichelli M, Morselli A, Ormes JF, Papini P, Piccardi P, Picozza P, Ricci M, Salvatori I, Spillantini P, Spinelli P, Stephens SA, Stochaj SJ, Streitmatter RE, Webber WR.
PMID: 10019770
Phys Rev D Part Fields. 1996 Jan 01;53(1):35-43. doi: 10.1103/physrevd.53.35.

No abstract available.

Cite
Basini G, Bellotti R, Bongiorno F, et al. Measurement of the negative muon spectrum between 0.3 and 40 GeV/c in the atmosphere. Phys Rev D Part Fields. 1996;53(1):35-43doi: 10.1103/physrevd.53.35.
Basini, G., Bellotti, R., Bongiorno, F., Brunetti, M. T., Cafagna, F., Circella, M., Codino, A., De Cataldo G, De Marzo CN, De Pascale MP, Giglietto, N., Golden, R. L., Grimani, C., Massimo Brancaccio F, Menichelli, M., Morselli, A., Ormes, J. F., Papini, P., Piccardi, P., Picozza, P., Ricci, M., Salvatori, I., Spillantini, P., Spinelli, P., Stephens, S. A., Stochaj, S. J., Streitmatter, R. E., & Webber, W. R. (1996). Measurement of the negative muon spectrum between 0.3 and 40 GeV/c in the atmosphere. Physical review. D, Particles and fields, 53(1), 35-43. https://doi.org/10.1103/physrevd.53.35
Basini, et al. "Measurement of the negative muon spectrum between 0.3 and 40 GeV/c in the atmosphere." Physical review. D, Particles and fields vol. 53,1 (1996): 35-43. doi: https://doi.org/10.1103/physrevd.53.35
Basini G, Bellotti R, Bongiorno F, Brunetti MT, Cafagna F, Circella M, Codino A, De Cataldo G, De Marzo CN, De Pascale MP, Giglietto N, Golden RL, Grimani C, Massimo Brancaccio F, Menichelli M, Morselli A, Ormes JF, Papini P, Piccardi P, Picozza P, Ricci M, Salvatori I, Spillantini P, Spinelli P, Stephens SA, Stochaj SJ, Streitmatter RE, Webber WR. Measurement of the negative muon spectrum between 0.3 and 40 GeV/c in the atmosphere. Phys Rev D Part Fields. 1996 Jan 01;53(1):35-43. doi: 10.1103/physrevd.53.35. PMID: 10019770.
Copy Download .nbib Format: NLM
Sex pheromone components of the European goat moth,Cossus cossus.

Journal of chemical ecology

Capizzi A, Tonini C, Arsura E, Guglielmetti G, Massardo P, Piccardi P.
PMID: 24407337
J Chem Ecol. 1983 Feb;9(2):191-200. doi: 10.1007/BF00988036.

Female tip washings of the European goat moth,Cossus cossus L., were found to contain the following compounds that are structurally similar to known pheromone components of Lepidoptera (%): decyl acetate (1.5), (Z)-5-dodecenol (1), (Z)-5-dodecenyl acetate (66), dodecyl acetate (12),...

Cite
Capizzi A, Tonini C, Arsura E, et al. Sex pheromone components of the European goat moth,Cossus cossus. J Chem Ecol. 1983;9(2):191-200doi: 10.1007/BF00988036.
Capizzi, A., Tonini, C., Arsura, E., Guglielmetti, G., Massardo, P., & Piccardi, P. (1983). Sex pheromone components of the European goat moth,Cossus cossus. Journal of chemical ecology, 9(2), 191-200. https://doi.org/10.1007/BF00988036
Capizzi, A, et al. "Sex pheromone components of the European goat moth,Cossus cossus." Journal of chemical ecology vol. 9,2 (1983): 191-200. doi: https://doi.org/10.1007/BF00988036
Capizzi A, Tonini C, Arsura E, Guglielmetti G, Massardo P, Piccardi P. Sex pheromone components of the European goat moth,Cossus cossus. J Chem Ecol. 1983 Feb;9(2):191-200. doi: 10.1007/BF00988036. PMID: 24407337.
Copy Download .nbib Format: NLM
Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.

Cancer medicine

Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P.
PMID: 34796694
Cancer Med. 2021 Nov 18; doi: 10.1002/cam4.4371. Epub 2021 Nov 18.

Triple negative breast cancers (TNBCs) are very aggressive and have a poor prognosis due to lack of efficacious therapies. The only effective treatment is chemotherapy that however is frequently hindered by the occurrence of drug resistance. We approached this...

Cite
Balza E, Carlone S, Carta S, et al. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med. 2021;doi: 10.1002/cam4.4371.
Balza, E., Carlone, S., Carta, S., Piccioli, P., Cossu, V., Marini, C., Sambuceti, G., Rubartelli, A., & Castellani, P. (2021). Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer medicine, . https://doi.org/10.1002/cam4.4371
Balza, Enrica, et al. "Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models." Cancer medicine vol. (2021). doi: https://doi.org/10.1002/cam4.4371
Balza E, Carlone S, Carta S, Piccioli P, Cossu V, Marini C, Sambuceti G, Rubartelli A, Castellani P. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer Med. 2021 Nov 18; doi: 10.1002/cam4.4371. Epub 2021 Nov 18. PMID: 34796694.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries